BGLAP and prostate cancer: Moreover, Surv.m-CRA-OCp, in which mutant E1B (E1B55K-deletion) expression is regulated by the osteosarcoma/prostate cancer-specific but weakly active osteocalcin promoter, significantly increased cancer specificity without decreasing anticancer effects against osteosarcoma and prostate cancer [68].